Preclinical results show potential new drug effective against drug-resistant melanoma

[News]

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented...

More... (http://www.medicalnewstoday.com/releases/267694.php)